Get the Stockscreener App
8.32
5.18%
0.41
After Hours:
8.08
-0.24
-2.88%
Immatics N V stock is traded at $8.32, with a volume of 272.32K.
It is up +5.18% in the last 24 hours and down -11.11% over the past month.
Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.
See More
Previous Close:
$7.91
Open:
$7.88
24h Volume:
272.32K
Relative Volume:
0.46
Market Cap:
$1.01B
Revenue:
$58.49M
Net Income/Loss:
$-105.04M
P/E Ratio:
-7.017
EPS:
-1.1857
Net Cash Flow:
$-13.78M
1W Performance:
+9.62%
1M Performance:
-11.11%
6M Performance:
-27.97%
1Y Performance:
-3.26%
1-Day Range:
$7.86
$8.36
1-Week Range:
$7.475
$8.36
52-Week Range:
$7.46
$13.77
Immatics N V Stock (IMTX) Company Profile
Compare IMTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMTX
Immatics N V
|
8.32 | 1.01B | 58.49M | -105.04M | -13.78M | -1.2997 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 120.56B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.22 | 82.44B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
616.55 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.07 | 32.64B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.39 | 28.38B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immatics N V Stock (IMTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-24 | Initiated | Piper Sandler | Overweight |
| Nov-02-23 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Mar-24-23 | Initiated | Bryan Garnier | Buy |
| Nov-20-20 | Initiated | BofA Securities | Buy |
| Sep-22-20 | Initiated | Goldman | Buy |
| Jul-27-20 | Initiated | SVB Leerink | Outperform |
| Jul-24-20 | Initiated | Jefferies | Buy |
View All
Immatics N V Stock (IMTX) Latest News
Braidwell LP Takes $18.80 Million Position in Immatics (NASDAQ:IMTX) - MarketBeat
Immatics (NASDAQ:IMTX) is Vestal Point Capital LP's 9th Largest Position - MarketBeat
Immatics (NASDAQ:IMTX) Upgraded by The Goldman Sachs Group to "Strong-Buy" Rating - MarketBeat
Exscientia (NASDAQ:EXAI) & Immatics (NASDAQ:IMTX) Head to Head Comparison - Defense World
Immatics N.V. Reports Strong Q3 2024 Progress and Financials - TipRanks
Cantor Fitzgerald Raises Earnings Estimates for Immatics - Defense World
Immatics FY2024 EPS Forecast Boosted by Cantor Fitzgerald - MarketBeat
Analysts Set Expectations for Immatics FY2024 Earnings - Defense World
FY2024 EPS Estimates for Immatics Increased by Analyst - MarketBeat
Immatics (NASDAQ:IMTX) Reaches New 1-Year Low Following Analyst Downgrade - Defense World
Bank of America Has Lowered Expectations for Immatics (NASDAQ:IMTX) Stock Price - Defense World
Immatics N.V. (NASDAQ:IMTX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Yahoo Finance
10 Best German Stocks To Buy Now - Insider Monkey
Is Immatics N.V. (IMTX) the Best German Stock to Buy Now? - Insider Monkey
Bank of America Issues Pessimistic Forecast for Immatics (NASDAQ:IMTX) Stock Price - MarketBeat
Immatics Sees Revenue Surge Despite R&D Expenses - Yahoo Finance
Immatics: Q3 Earnings Snapshot - Milford Mirror
Immatics NV earnings beat by €0.14, revenue topped estimates - Investing.com UK
What Makes Immatics (IMTX) a New Buy Stock - Yahoo Finance
Immatics N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Immatics reports Q3 EPS (EUR 0.11) vs. (EUR 0.32) last year - TipRanks
Immatics (IMTX) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Immatics announces clinical data on TCER IMA402 targeting PRAME - TipRanks
Immatics sees cash runway into 2H27 - TipRanks
Immatics Announces Third Quarter 2024 Financial Results, - GlobeNewswire
Immatics Reports Early Success in Melanoma Treatment, Plans Phase 3 Trial as Cash Position Tops $699M | IMTX Stock News - StockTitan
T. Rowe Price Investment Management, Inc. Reduces Stake in Immatics NV - GuruFocus.com
Immatics (NASDAQ:IMTX) Reaches New 52-Week LowShould You Sell? - MarketBeat
When the Price of (IMTX) Talks, People Listen - Stock Traders Daily
Immatics N.V. Warrants (IMTXW) SEC Filing Summary - Quartzy
IMTX (Immatics NV) FCF Yield % : -4.41 (As of Nov. 11, 2024) - GuruFocus.com
Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME - 新浪香港
Immatics Unveils Promising TCR-T Therapy Developments - TipRanks
Immatics Announces Multiple Presentations at the 39th - GlobeNewswire
Wellington Management Group LLP Increases Stake in Immatics NV - GuruFocus.com
Piper Sandler Initiates Coverage of Immatics N.V. (IMTX) with Overweight Recommendation - MSN
Immatics (IMTX) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
232,900 Shares in Immatics (NASDAQ:IMTX) Bought by abrdn plc - MarketBeat
Objective long/short (IMTX) Report - Stock Traders Daily
Short Interest in Immatics (NASDAQ:IMTX) Expands By 5.3% - MarketBeat
Shareholders in Immatics (NASDAQ:IMTX) have lost 35%, as stock drops 6.3% this past week - Simply Wall St
Immatics N.V. (NASDAQ:IMTX) is a favorite amongst institutional investors who own 50% - Yahoo Finance
Perceptive Advisors LLC Reduces Stake in Immatics NV - Yahoo Finance
Immatics N.V. Announces Major Share Offering - TipRanks
Market Update: Immatics N.V (IMTX) Sees Negative Movement, Closing at 9.30 - The Dwinnex
Immatics N V Stock (IMTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):